Report Sections

See All Reports

  • HP:0012622: Chronic kidney disease
  • Pneumonia (312) Abnormality of the cardiovascular system (29) Neoplasm (27) Respiratory tract infection (27) Hypoxemia (22) Depressivity (21) Diabetes mellitus (19) Acute kidney injury (19) Abnormal lung morphology (19) Thromboembolism (17) Hypertension (16) Anosmia (14) Myocardial infarction (14) Abnormality of coagulation (14) Stroke (13) Pulmonary embolism (13) Arthritis (12) Leukemia (12) Interstitial pneumonitis (12) Autistic behavior (11) Mental deterioration (11) Deep venous thrombosis (10) Type II diabetes mellitus (10) Pulmonary obstruction (10) Crohn's disease (10) Abnormality of the kidney (9) Autism (9) Obesity (9) Congestive heart failure (9) Chronic pulmonary obstruction (9) Chronic pain (9) Rheumatoid arthritis (8) Abnormality of the liver (8) Respiratory distress (8) Pulmonary fibrosis (8) Colitis (8) Myocarditis (8) Carcinoma (8) Ulcerative colitis (8) Behavioral abnormality (7) Dementia (7) Infertility (7) Inflammation of the large intestine (7) Pulmonary insufficiency (7) Low levels of vitamin D (7) Neoplasm of the lung (7) Type I diabetes mellitus (7) Psychosis (6) Coronary artery atherosclerosis (6) Lymphoma (6) Abnormality of the gastrointestinal tract (6) Chronic kidney disease (6) Sepsis (6) Renal insufficiency (5) Lymphopenia (5) Gastroparesis (5) Immunodeficiency (5) Systemic lupus erythematosus (5) Breast carcinoma (5) Peripheral arterial stenosis (5) Allergy (5) Encephalopathy (4) Hepatic fibrosis (4) Cardiac arrest (4) Dysphagia (4) Asthma (4) Alzheimer disease (4) Osteoarthritis (4) Neoplasm of the pancreas (4) Autoimmunity (4) Disseminated intravascular coagulation (4) Attention deficit hyperactivity disorder (4) Sleep apnea (4) Prostate cancer (4) Neoplasm of head and neck (4) Addictive behavior (4) Insomnia (4) Obsessive-compulsive behavior (3) Seizure (3) Cardiomyopathy (3) Weight loss (3) Fever (3) Migraine (3) Pulmonary arterial hypertension (3) Bronchiectasis (3) Obstructive sleep apnea (3) Colon cancer (3) Reduced factor VIII activity (3) Malnutrition (3) Knee osteoarthritis (3) Lymphoid leukemia (3) Renal cell carcinoma (3) Arrhythmia (3) Fatigue (3) Endometriosis (3) Non-small cell lung carcinoma (3) Neuroendocrine neoplasm (3) Hypercoagulability (3) Schizophrenia (3) Hearing impairment (2) Visual impairment (2) Conjunctivitis (2) Uveitis (2) Agoraphobia (2) Abnormality of the endocrine system (2) Abnormal heart morphology (2) Tachycardia (2) Angina pectoris (2) Gastroesophageal reflux (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Mutism (2) Headache (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Atherosclerosis (2) Hypoventilation (2) Myelodysplasia (2) Psoriasiform dermatitis (2) Paroxysmal atrial fibrillation (2) Acute myeloid leukemia (2) Lymphoproliferative disorder (2) Myeloproliferative disorder (2) Multiple myeloma (2) Intervertebral disc degeneration (2) Stridor (2) Cystoid macular edema (2) Hemeralopia (2) Cutaneous melanoma (2) Arteritis (2) Glioblastoma multiforme (2) Cervix cancer (2) Pulmonary edema (2) Ovarian neoplasm (2) Angioedema (2) Mania (2) Neoplasm of the large intestine (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Hypogeusia (1) Conductive hearing impairment (1) Abnormality of the eye (1) Cataract (1) Amblyopia (1) Periodontitis (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Abnormality of the skin (1) Jaundice (1) Lymphedema (1) Angiokeratoma corporis diffusum (1) Keratoconjunctivitis (1) Spasticity (1) Hemiparesis (1) Polyneuropathy (1) Syncope (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic steatosis (1) Hepatic failure (1) Hepatocellular carcinoma (1) Premature birth (1) Sudden cardiac death (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Pancreatitis (1) Abnormality of blood and blood-forming tissues (1) Gout (1) Diarrhea (1) Anorexia (1) Esophageal varix (1) Hypothermia (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Encephalitis (1) Waddling gait (1) Increased intracranial pressure (1) Celiac disease (1) Biliary cirrhosis (1) Hypotension (1) Osteomyelitis (1) Squamous cell carcinoma (1) Central apnea (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Skeletal muscle atrophy (1) Male infertility (1) Spondylolisthesis (1) Myalgia (1) Back pain (1) Low back pain (1) Muscular dystrophy (1) Neonatal death (1) Thrombophlebitis (1) Chronic bronchitis (1) Ventricular tachycardia (1) Coronary artery stenosis (1) Chronic lymphatic leukemia (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Abnormal anterior horn cell morphology (1) Amyotrophic lateral sclerosis (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Stomatitis (1) Uterine neoplasm (1) Intestinal atresia (1) Inflammatory abnormality of the skin (1) Sinus tachycardia (1) Bronchiolitis (1) Postprandial hyperglycemia (1) Hepatitis (1) Erythroid hypoplasia (1) Hodgkin lymphoma (1) B-cell lymphoma (1) Myeloid leukemia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Bronchitis (1) Hypercapnia (1) Pain (1) Retinal vein occlusion (1) Vasovagal syncope (1) Neonatal asphyxia (1) Dyspareunia (1) Heart murmur (1) Cardiogenic shock (1) Cholangitis (1) Cholangiocarcinoma (1) Small cell lung carcinoma (1) Vulvar neoplasm (1) Neonatal sepsis (1) Glue ear (1) Subdural hemorrhage (1) Endocarditis (1) Toxemia of pregnancy (1) Myositis (1) Vaginal neoplasm (1) Cellulitis (1) Self-injurious behavior (1) Bulimia (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0012622: Chronic kidney disease

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (12)


    Name (Synonyms) Correlation
    drug1243 Exercise training group Wiki 0.41
    drug2732 Quantitative IgG Test Wiki 0.41
    drug136 AZD5718 Wiki 0.41
    Name (Synonyms) Correlation
    drug1712 Intervention-EDI and health coaching Wiki 0.41
    drug892 Control-EDI Wiki 0.41
    drug936 Covid-19 Rapid Test Kit (RAPG-COV-019) Wiki 0.41
    drug991 Dapagliflozin 10 mg Wiki 0.41
    drug401 BI 764198 Wiki 0.29
    drug3639 Verinurad Wiki 0.24
    drug213 Allopurinol Wiki 0.24
    drug954 Cyclosporine Wiki 0.18
    drug2505 Placebo Wiki 0.04

    Correlated MeSH Terms (6)


    Name (Synonyms) Correlation
    D051436 Renal Insufficiency, Chronic NIH 0.87
    D007674 Kidney Diseases NIH 0.74
    D002908 Chronic Disease NIH 0.23
    Name (Synonyms) Correlation
    D051437 Renal Insufficiency, NIH 0.18
    D007154 Immune System Diseases NIH 0.17
    D006973 Hypertension NIH 0.09

    Correlated HPO Terms (3)


    Name (Synonyms) Correlation
    HP:0000077 Abnormality of the kidney HPO 0.82
    HP:0000083 Renal insufficiency HPO 0.18
    HP:0000822 Hypertension HPO 0.10

    Clinical Trials

    Navigate: Correlations   HPO

    There are 6 clinical trials


    1 Controlling Hypertension Through Education and Coaching in Kidney Disease

    Chronic kidney disease (CKD) is a serious and growing public health problem. The purpose of this study is to find out if an educational worksheet, called the Encounter Decision Intervention (EDI), combined with health coaching helps CKD patients improve their blood pressure and other health outcomes. The research team hypothesizes that the intervention group will have greater improvement in CKD outcomes than the control group.

    NCT04087798
    Conditions
    1. Chronic Kidney Diseases
    2. Chronic Disease
    3. Chronic Kidney Disease, Stage 3 (Moderate)
    4. Chronic Kidney Disease, Stage 4 (Severe)
    5. Chronic Kidney Disease Stage 5
    Interventions
    1. Behavioral: Control-EDI
    2. Behavioral: Intervention-EDI and health coaching
    MeSH:Kidney Diseases Renal Insufficiency, Chronic Hypertension Chronic Disease
    HPO:Abnormality of the kidney Chronic kidney disease Hypertension Nephropathy

    Primary Outcomes

    Description: Changes in systolic blood pressure between baseline and 12 months will be compared between the intervention group and control group.

    Measure: Change in Systolic Blood Pressure between baseline and 12 months

    Time: Baseline, 12 months

    Secondary Outcomes

    Description: Changes in diastolic blood pressure between baseline and 12 months will be compared between the intervention group and control group.

    Measure: Change in Diastolic Blood Pressure between baseline and 12 months

    Time: Baseline, 12 months

    Description: BP will be collected at 4 time points - baseline, 1, 6, 12 months. This will be compared between the intervention group and control group.

    Measure: Slope of systolic BP between baseline and 12 months using all available BP values

    Time: Baseline up to 12 months

    Description: BP will be collected at 4 time points - baseline, 1, 6, 12 months. This will be compared between the intervention group and control group.

    Measure: Slope of diastolic BP between baseline and 12 months using all available BP values

    Time: Baseline up to 12 months

    Description: This is a 28-item questionnaire measuring objective CKD disease knowledge and includes questions about goals, cardiovascular risk, and anti-hypertensive medications. Patients will answer the questions with a yes or no answer and their score will be based on how many responses were correct. This number will be converted to a percentage.

    Measure: CKD knowledge measured by the Kidney Knowledge Survey (KiKS)

    Time: Baseline up to 12 months

    Description: This is a 13-item measure with the answers on a Likert scale of 1 (not at all sure) to 4 (extremely sure). The higher the score the higher the self-efficacy, with a range from 13-52.

    Measure: Medication Adherence Self-Efficacy Scale-Revised (MASES-R)

    Time: Baseline up to 12 months

    Description: This scale is to quantify adherence to pharmacological treatments by means of 8 items. Patients will answer yes or no to these items, where a no response = 1 point and a yes response = 0 points. Levels of adherence are based on the following scores: 3-8 = low adherence; 1-2 = medium adherence; 0 = high adherence.

    Measure: Morisky Medication Adherence Scale (MMAS - 8)

    Time: Baseline up to 12 months

    Description: Length of time provider spends with the patient. This will be compared between the intervention group and control group.

    Measure: Visit Time with provider

    Time: Enrollment visit (baseline)

    Description: Length of time between patient check-in and check-out. This will be compared between the intervention group and control group.

    Measure: Total time in clinic

    Time: Enrollment visit (baseline)

    Description: This contains a 17-item questionnaire in which the participants select scores from 1-7 or does not apply. A number of 1 = not at all and a score of 7 = considered very true, and zero = not applicable.

    Measure: Patient Motivation by the Treatment Self-Regulation Questionnaire scale (TSRQ)

    Time: Baseline up to 12 months

    Description: This is a 15-item questionnaire that assesses the quality of physician to patient communication completed by the patients. There are 5 answers to choose from; poor, fair, good, very good, and excellent. The Score range is 1-5, where 1 means negative perception of communication and 5 means positive perception of communication.

    Measure: Satisfaction with CKD care based on Communication Assessment Tool (CAT)

    Time: Baseline up to 12 months

    Description: This is a 21-item questionnaire that is completed by the patients, and select from the the 4 choices: very strongly agree, strongly agree, agree, and neutral/disagree. Each answer is worth one point on a Likert scale with a higher score meaning more satisfied.

    Measure: Satisfaction with CKD care based on Consultation Care Measure (CCM)

    Time: Baseline up to 12 months

    Description: During health coach phone calls, participants will be asked 37 questions about their perceptions of the health coach program, including how much their participation in CHECK-D helped participants change various behaviors. Participant responses will be used to examine various measures of reliability and validity during the analyses of data acquired though this survey.

    Measure: Perceptions of health coaching for the intervention group

    Time: Baseline up to 12 months

    Description: The EMR will be reviewed to evaluate the patients medication refills for adherence.

    Measure: Medication adherence from the electronic medical record (EMR)

    Time: Baseline up to 12 months

    Description: This is an 8-item scale regarding self-efficacy where each statement is rated on the level of agreement from 1-5. 1 is disagree and 5 is agree.

    Measure: Self-efficacy for disease self-management based on The Perceived Kidney/Dialysis Self-Management Scale (PKDSMS)

    Time: Baseline up to 12 months

    Description: This is a 5-item survey about knowledge and behaviors regarding sodium in the diet.

    Measure: Self-reported Blood Pressure-Related Behaviors Survey

    Time: Baseline up to 12 months

    Description: Provider adoption will be measured by the percentage of enrolled patients whose providers used the EDI with them during their visit. Data will be collected by EMR query and a 1-item question in the patient survey.

    Measure: Provider Adoption based on EMR query and patient survey

    Time: Baseline

    Description: Provider fidelity will be measured by the percentage of enrolled patients in the intervention clinics whose providers entered 1-2 patient specific goals in the EDI. This will be collected through EMR query.

    Measure: Provider Fidelity measured by EMR query

    Time: Baseline

    Description: Provider perception of usefulness will be measured by a survey of 2-3 questions about how useful they thought it was.

    Measure: Provider Perception of Usefulness by provider survey

    Time: Baseline up to 12 months

    Description: Change in Serum Creatinine between baseline and 12-months

    Measure: Change in serum creatinine

    Time: Baseline, 12 months

    Measure: Change in urine protein-creatinine ratio

    Time: Baseline, 12 months

    Measure: Change in estimated glomerular filtration rate (eGFR)

    Time: Baseline, 12 months
    2 Pharmacokinetics, Safety and Tolerability After Single Dose Administration of BI 764198 in Subjects With Moderate and Severe Renal Impairment in Comparison to Subjects With Normal Renal Function (a Mono-centric, Open-label Study With Matched-pair Design)

    The main objective of this trial is to investigate the influence of moderate and severe renal impairment on the pharmacokinetics of a single dose of BI 764198 in comparison to a group of matched controls with normal renal function.

    NCT04176536
    Conditions
    1. Healthy
    2. Chronic Kidney Disease
    Interventions
    1. Drug: BI 764198
    MeSH:Kidney Diseases Renal Insufficiency, Chronic
    HPO:Abnormality of the kidney Chronic kidney disease Nephropathy

    Primary Outcomes

    Measure: AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)

    Time: Up to 96 hours

    Measure: Cmax (maximum measured concentration of the analyte in plasma)

    Time: Up to 96 hours

    Secondary Outcomes

    Measure: AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 the last quantifiable data point)

    Time: Up to 96 hours
    3 Single-Centre, Randomised, Double-Blind, 3-Period Cross-Over Study to Investigate Effects on QTcF Interval of Verinurad ER 24 mg or IR 40 mg in Combination With Allopurinol 300 mg, Compared to Matching Placebos In Healthy Volunteers

    This study will be conducted to investigate the safety of verinurad in healthy volunteers in combination with allopurinol 300 mg, compared with placebo in particular its effect on electrocardiogram (ECG), with focus on the QT/QTc interval

    NCT04256629
    Conditions
    1. Healthy Volunteers (Intended Indication: Chronic Kidney Disease)
    Interventions
    1. Drug: Verinurad
    2. Drug: Placebo
    3. Drug: Allopurinol
    MeSH:Kidney Diseases Renal Insufficiency, Chronic
    HPO:Abnormality of the kidney Chronic kidney disease Nephropathy

    Primary Outcomes

    Description: To assess the effect of a single dose of verinurad given as either a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supra-therapeutic exposure), both in combination with allopurinol 300 mg, on the QTcF interval compared to placebo using a concentration-QTcF interval analysis

    Measure: Maximum observed plasma concentration (Cmax)

    Time: Visit 2,3,4:- Day 1: Pre-dose, 0.5,1,1.5,2, 3, 4, 5, 6, 7, 8 and 12 hours post-dose; Day 2: 24 and 36 hours post-dose; Day 3: 48 hours post-dose

    Description: To assess the effect of a single dose of verinurad given as either a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supra-therapeutic exposure), both in combination with allopurinol 300 mg, on the QTcF interval compared to placebo using a concentration-QTcF interval analysis

    Measure: Baseline-corrected and placebo-adjusted QTcF interval (ΔΔQTcF)

    Time: Screening; Visit 2,3,4:- Day -1, 1,2, 3; Follow up visit (7 to 10 days after the last dose)

    Secondary Outcomes

    Description: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation(supratherapeutic exposure), both in combination with allopurinol 300 mg

    Measure: Baseline-corrected heart rate (ΔHR)

    Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

    Description: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supratherapeutic exposure), both in combination with allopurinol 300 mg

    Measure: Baseline-corrected and placebo-adjusted heart rate (ΔΔHR)

    Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

    Description: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supratherapeutic exposure), both in combination with allopurinol 300 mg

    Measure: Baseline-corrected RR interval (ΔRR interval)

    Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

    Description: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supratherapeutic exposure), both in combination with allopurinol 300 mg

    Measure: Baseline-corrected and placebo-adjusted RR interval (ΔΔRR interval)

    Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

    Description: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supratherapeutic exposure), both in combination with allopurinol 300 mg

    Measure: Baseline-corrected PR interval (ΔPR interval)

    Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

    Description: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supratherapeutic exposure), both in combination with allopurinol 300 mg

    Measure: Baseline-corrected and placebo-adjusted PR interval (ΔΔPR interval)

    Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

    Description: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supratherapeutic exposure), both in combination with allopurinol 300 mg

    Measure: Baseline-corrected and placebo-adjusted QRS interval (ΔQRS interval)

    Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

    Description: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supratherapeutic exposure), both in combination with allopurinol 300 mg

    Measure: Baseline-corrected and placebo-adjusted QRS interval (ΔΔQRS interval)

    Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

    Description: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supratherapeutic exposure), both in combination with allopurinol 300 mg

    Measure: Baseline-corrected QT interval (ΔQT interval)

    Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

    Description: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supratherapeutic exposure), both in combination with allopurinol 300 mg

    Measure: Baseline-corrected and placebo-adjusted QT interval (ΔΔQT interval)

    Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

    Description: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supratherapeutic exposure), both in combination with allopurinol 300 mg

    Measure: Baseline-corrected QTcF interval (ΔQTcF interval)

    Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

    Description: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supratherapeutic exposure), both in combination with allopurinol 300 mg

    Measure: Baseline-corrected and placebo-adjusted QTcF interval (ΔΔQTcF interval)

    Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

    Description: To assess the pharmacokinetics (PK) of verinurad and its metabolites (M1 and M8) and allopurinol and its metabolite (oxypurinol) in healthy subjects

    Measure: Area under plasma concentration-time curve from zero to infinity (AUC)

    Time: Visit 2, 3 and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose

    Description: To assess the PK of verinurad and its metabolites (M1 and M8) and allopurinol and its metabolite (oxypurinol) in healthy subjects.

    Measure: Area under the plasma concentration-curve from time zero to time of last quantifiable concentration (AUC0-t)

    Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

    Description: To assess the PK of verinurad and its metabolites (M1 and M8) and allopurinol and its metabolite (oxypurinol) in healthy subjects

    Measure: Maximum observed plasma concentration (Cmax)

    Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post dose

    Description: To assess the PK of verinurad and its metabolites (M1 and M8) and allopurinol and its metabolite (oxypurinol) in healthy subjects

    Measure: Time to reach maximum observed plasma concentration (tmax)

    Time: Visit 2, 3 and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose

    Description: To assess the PK of verinurad and its metabolites (M1 and M8) and allopurinol and its metabolite (oxypurinol) in healthy subjects

    Measure: Time delay between drug administration and the first observed concentration in plasma (tlag)

    Time: Visit 2, 3 and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose

    Description: To assess the PK of verinurad and its metabolites (M1 and M8) and allopurinol and its metabolite (oxypurinol) in healthy subjects

    Measure: Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½λz)

    Time: Visit 2, 3 and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose

    Description: To assess the PK of verinurad and its metabolites (M1 and M8) and allopurinol and its metabolite (oxypurinol) in healthy subjects

    Measure: Time of last quantifiable plasma concentration (tlast)

    Time: Visit 2, 3 and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose

    Description: To assess the PK of verinurad and its metabolites (M1 and M8) and allopurinol and its metabolite (oxypurinol) in healthy subjects

    Measure: Apparent total body clearance of drug from plasma after extravascular administration (parent drug only) [CL/F]

    Time: Visit 2, 3 and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose

    Description: To assess the PK of verinurad and its metabolites (M1 and M8) and allopurinol and its metabolite (oxypurinol) in healthy subjects

    Measure: Apparent volume of distribution during the terminal phase after extravascular administration (parent drug only) [Vz/F]

    Time: Visit 2, 3 and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose

    Description: To assess the PK of verinurad and its metabolites (M1 and M8) and allopurinol and its metabolite (oxypurinol) in healthy subjects

    Measure: Apparent volume of distribution at steady state (Vss/F)

    Time: Visit 2, 3 and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose

    Description: To assess the PK of verinurad and its metabolites (M1 and M8) and allopurinol and its metabolite (oxypurinol) in healthy subjects

    Measure: Mean residence time of the unchanged drug in the systemic circulation from zero to infinity (MRT)

    Time: Visit 2, 3 and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose

    Description: To assess clinical chemistry/hematology/urinalysis as a variable of safety and tolerability of verinurad and allopurinol

    Measure: Number of subjects with abnormal haematology, clinical chemistry and urinalysis

    Time: Screening; Visit 2,3 and 4:- Day -1, Day 3: 48 h post-dose, Follow up period

    Description: To assess vital signs as a variable of safety and tolerability of verinurad and allopurinol

    Measure: Number of subjects with abnormal blood pressure and pulse rate

    Time: Screening; Visit 2,3 and 4:- Day -1, Day 1: pre-dose, 1 and 6 h post-dose; Day 2: 24 h post-dose; Day 3: 48 h post-dose, Follow up visit
    4 Online, Home-based, Aerobic Training Program Among Adolescents With Chronic Diseases During COVID-19 Pandemic: A Randomized Controlled Trial

    Data show that the coronavirus disease 2019 (COVID-19) symptoms can be severe in 4% and 3% of the adolescents aged 11-15 years and ≥ 16 years, respectively. In addition, the prevalence of chronic diseases among adolescents has increased in the last years. About 20% of the adolescents have some chronic disease, resulting in increased morbidity and mortality. In march, 2020, the quarantine was officially implemented in Sao Paulo, while elective medical appointments for adolescents with chronic disease were temporarily suspended. To mitigate the deleterious effect of the social isolation on physical and mental health among these patients, this study aims to test the effects of an online, home-based, exercise training program.

    NCT04458246
    Conditions
    1. Chronic Disease
    2. Chronic Diseases in Adolescence
    3. Chronic Disease of Immune System
    4. Chronic Kidney Diseases
    Interventions
    1. Other: Exercise training group
    MeSH:Kidney Diseases Renal Insufficiency, Chronic Immune System Diseases Chronic Disease
    HPO:Abnormality of the kidney Chronic kidney disease Nephropathy

    Primary Outcomes

    Description: Semi structured interview

    Measure: Safety and efficacy of a home-based exercise training program

    Time: From baseline to 3 months of follow-up

    Secondary Outcomes

    Description: Semi structured interview

    Measure: Patients perceptions during social isolation

    Time: From baseline to 3 months of follow-up

    Description: Quality of life will be assessed by means of Pediatric Quality of Life inventory (PedsQLTM 4.0)

    Measure: Adolescents quality of life

    Time: From baseline to 3 months of follow-up

    Description: Will be assessed by means of a visual analog scale (from 0 - no disease activity) to 10 - maximum disease activity).

    Measure: Disease activity

    Time: From baseline to 3 months of follow-up

    Description: Will be assessed using the visual analog scale from 0 (very good condition) to 10 (very poor condition).

    Measure: Disease overall assessment

    Time: From baseline to 3 months of follow-up

    Description: Will be assessed by means of Strengths & Difficulties Questionnaires

    Measure: Strengths and difficulties

    Time: From baseline to 3 months of follow-up
    5 Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection

    The coronavirus (COVID-19) pandemic has created a significant strain on health care resources across the world for managing critically ill patients. Emerging reports from China, South Korea and Italy have reported varying incidence of acute kidney (AKI) ranging from 5-15% with a mortality of 60-80% however there is no systematic assessment of the risk factors, recognition, course and outcomes in patients with and without kidney disease whose course is complicated by AKI1-4. Patients with underlying CKD, immunosuppressed patients with renal transplants and ESKD patients are at high risk for COVID-19 infection and there is limited information on the effect of COVID-19 on the course and outcomes of these patients. The requirement for renal support including IHD, CRRT and sorbent based therapies has been variable and has contributed to the intense pressure on the nephrology and critical care providers for delivering these therapies. As the COVID-19 pandemic expands in the USA and abroad, there is an intense need to understand the epidemiology of the disease and the resources needed for renal support to inform clinical management and public health interventions. In this study, the investigators aim to investigate health care facilities across the world (hospital wards, ICU, outpatient clinics, nursing homes, healthcare centers) to draw a global picture of incidence, risk factors, resources available for treatment and prognosis of acute and chronic kidney disease in patient with COVID 19 confirmed infection. The aim is to identify trends in patients with acute and chronic kidney disease, determine its incidence, treatment and outcomes in different settings across the world. This information will be used to develop and implement educational tools and resources to prevent deaths from AKI and progression of CKD in this and following pandemics.

    NCT04491227
    Conditions
    1. Covid19
    2. AKI
    3. CKD
    4. ESRD
    5. Transplant;Failure,Kidney
    MeSH:Kidney Diseases Renal Insufficiency, Chronic Renal Insufficiency
    HPO:Abnormality of the kidney Chronic kidney disease Nephropathy Renal insufficiency

    Primary Outcomes

    Description: Meeting of at least one of the modified KDIGO Criteria Increase or decrease in serum creatinine >0.3 mg/dl from reference in 48 hours Increase or decrease in serum creatinine > 50% from reference in 7 days Urine output < 400 ml/day

    Measure: AKI incidence

    Time: from hospital admission through hospital discharge upto 24 weeks

    Description: initiation of intermittent hemodialysis, continuous hemodialysis or peritoneal dialysis during the hospital stay

    Measure: Dialysis requirement

    Time: through study completion upto 1 year from enrollment

    Description: Deaths during primary hospitalization

    Measure: hospital mortality

    Time: through study completion within 1 year

    Secondary Outcomes

    Description: C-Complete: SCr < 0.3 mg/dL from reference P-Partial: Requires no dialysis but not complete recovery N-No recovery: Dialysis dependent C-Complete: SCr < 0.3 mg/dL from reference P-Partial: Requires no dialysis but not complete recovery N-No recovery: Dialysis dependent Percentage of patinets with renal functioanl recovery based on serum creatinien levels classfied as C-Complete: SCr < 0.3 mg/dL from reference P-Partial: Requires no dialysis but not complete recovery N-No recovery: Dialysis dependent

    Measure: Renal functional recovery

    Time: Assessed at at 3, 6 and 12 months from enrollment at hospital admission

    Description: EQL5D scale and SH8 scales completed at 3, 6 and 12 months post enrollment

    Measure: Functional status

    Time: questionnaires to be completed at 3, 6 and 12 months from enrollment at hospital admission

    Description: Number of days patient is in the hospital and ICU and is managed with ventilators, dialysis or other extracorporeal organ support e.g. ECMO during the hospital stay

    Measure: Resource utilization

    Time: Within 1 year of enrollment for primary hospitalization
    6 A Phase 2b Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Dose-Ranging Study of AZD5718 in Participants With Proteinuric Chronic Kidney Disease

    The purpose of the study is to evaluate the dose-response efficacy, safety, and pharmacokinetics (PK) of AZD5718 in participants with proteinuric chronic kidney disease.

    NCT04492722
    Conditions
    1. Chronic Kidney Disease
    Interventions
    1. Drug: AZD5718
    2. Drug: Dapagliflozin 10 mg
    3. Drug: Placebo
    MeSH:Kidney Diseases Renal Insufficiency, Chronic
    HPO:Abnormality of the kidney Chronic kidney disease Nephropathy

    Primary Outcomes

    Description: To evaluate the dose response effect of AZD5718 on urine ACR at 20 weeks

    Measure: Change from baseline in urine ACR to Week 20

    Time: Week 1 to Week 20

    Secondary Outcomes

    Description: To evaluate the dose response effect of AZD5718 on urine ACR at 12 weeks

    Measure: Change from baseline in urine ACR to Week 12

    Time: Week 1 to Week 12

    Description: To assess the safety and tolerability profile of AZD5718 treatment

    Measure: Number of participants with adverse events and serious adverse events

    Time: Screening to Week 24

    Description: To evaluate the effect of AZD5718 on ambulatory blood pressure

    Measure: Change from baseline in 24-hours mean systolic blood pressure to Week 12

    Time: Week 1 to Week 12

    Description: To assess the PK of AZD5718 after repeated oral dosing for 20 weeks

    Measure: Plasma concentrations of AZD5718

    Time: Week 2 to Week 20

    Description: To assess the effect of AZD5718 on renal function

    Measure: Change from baseline in estimated glomerular filtration rate (eGFR) to Week 12

    Time: Week 1 to Week 12

    HPO Nodes


    Reports

    Data processed on September 26, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,180 reports on interventions/drugs

    MeSH

    691 reports on MeSH terms

    HPO

    263 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook